Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Rhea-AI Summary
Geron (Nasdaq: GERN) announced it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time, accessible via the Investors and Media section of its website.
Positive
- None.
Negative
- None.
News Market Reaction – GERN
In the Jul 22 session, GERN declined 2.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Earnings date notice | Neutral | +3.3% | Scheduled first-quarter results and business highlights before the May 6 market open |
| Feb 11 | Earnings date notice | Neutral | -0.6% | Scheduled fourth-quarter and full-year results before the February 25 market open |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two prior earnings-date notices produced mixed 24-hour reactions, with one positive move and one negative move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com